Drug intelligence / Profile preview

BSI-729

Development stage: Preclinical
Lead developer: Biosion
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BSI-729 is a preclinical-stage bispecific antibody being developed by Biosion for the treatment of solid tumors. It is described as a "first-in-class" therapeutic candidate, though its specific molecular targets and detailed mechanism of action have not been publicly disclosed. The drug is developed using Biosion's proprietary platforms, which include the H³ antibody discovery platform and the Flexibody® bispecific platform, aimed at creating novel treatments for various neoplasms.

Beyond the preview

Go deeper on BSI-729.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSI-729.

Explore the full profile